Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Blood and CSF metabolomics identifies tryptophan catabolism and polyamine synthesis as drivers of CAR T-cell-associated neurotoxicity

Soumya Poddar, Darawan Rinchai, Madison Davis et al. Nov 03, 2025 pp. 805-805 10.1182/blood-2025-805

Abstract Background: Anti-CD19 chimeric antigen receptor (CAR) T-cell therapies have demonstrated durable responses and...

Role of ADAMTS13 and von Willebrand factor in pathogenesis of experimental preeclampsia in rats

Zhirong Chai, Zhijian Wu, Liang Zheng et al. Nov 03, 2025 pp. 3098-3098 10.1182/blood-2025-3098

Abstract Introduction: Preeclampsia, a serious complication of pregnancy that occurs at ≥20 weeks of gestation, is characterized primarily b...

Trends in mortality due to hematological malignancies among diabetic patients aged 25 and older in the u.S. (1999–2023): A 24-year CDC wonder database analysis

Eshal Saghir, Muhammad Affan, Mahtab Zafar et al. Nov 03, 2025 pp. 7186-7186 10.1182/blood-2025-7186

Abstract Introduction: Hematologic malignancies—including multiple myeloma, non-Hodgkin lymphoma, and leukemia—are more...

Ibrutinib plus rituximab leads to superior progression-free and overall survival to FCR in previously untreated CLL: Results of the Phase III NCRI FLAIR trial

Talha Munir, Sean Girvan, Annah Muli et al. Nov 03, 2025 pp. 2128-2128 10.1182/blood-2025-2128

Abstract Introduction: The most effective chemoimmunotherapy (CIT) in previously untreated CLL is the combination of flu...

Outcomes of arthroplasty in persons with hemophilia: A survey of Medicare data

Mohamad Ali Tfaily, Tinatin Muradashvili, Christine Kempton et al. Nov 03, 2025 pp. 3064-3064 10.1182/blood-2025-3064

Abstract Background: The most common bleeding manifestation of hemophilia is bleeding into major joints. A significant percentage of persons...

The clinical trials landscape in chronic lymphocytic leukemia: A systematic review of control arm adequacy

Sai Pranav Kota, Ross Terada, Alexander Gorzewski et al. Nov 03, 2025 pp. 7415-7415 10.1182/blood-2025-7415

Abstract Background: Over the last decade, the standard of care (SOC) for previously untreated chronic lymphocytic leukemia (CLL) has transi...

Upfront maintenance therapy improves the prognosis of patients with diffuse large B-cell lymphoma in the era of novel agents: A multicenter retrospective study

Liwei Lv, Liu Zixian, Yan-ying Wang et al. Nov 03, 2025 pp. 7227-7227 10.1182/blood-2025-7227

Abstract Introduction Current first-line R-CHOP therapy achieves a cure in only 50–70% of diffuse large B-cell lymphoma (DLBCL) patients, wi...

Utilisation of machine learning algorithms to predict relapse risk following allogeneic stem cell transplantation (alloSCT) for patients with myeloid malignancies

Ray Mun Koo, Farhad Goodarzy, Eric Wong et al. Nov 03, 2025 pp. 6081-6081 10.1182/blood-2025-6081

Abstract Background: Disease relapse remains the primary cause of treatment failure following alloSCT for acute myeloid leukaemia (AML) and...

BCMA-targeted CAR T cells for multi-refractory primary immune thrombocytopenia: A pilot study

Jinhui Shu, Min Xu, Wei Xie et al. Nov 03, 2025 pp. 1267-1267 10.1182/blood-2025-1267

Abstract Background:Primary immune thrombocytopenia (ITP) is a bleeding disorder primarily driven by pathogenic anti-platelet autoantibodies...

Tazemetostat in Relapsed/Refractory follicular lymphoma and DLBCL: A systematic review of clinical trials

Nisheem Pokharel, Nehemias Guevara, Supriya Shrestha et al. Nov 03, 2025 pp. 7109-7109 10.1182/blood-2025-7109

Abstract Introduction Tazemetostat, an EZH2 inhibitor, received FDA approval (2020) for third-line treatment of relapsed...

Next-generation sequencing as a powerful tool for measurable residual disease assessment in pediatrics: Identifying time points of true remission

David McCall, Aline Hittle, Branko Cuglievan et al. Nov 03, 2025 pp. 3370-3370 10.1182/blood-2025-3370

Abstract Introduction Next-generation sequencing (NGS) is a sensitive tool for measurable residual disease (MRD) detection, particularly in a...

Trial in progress: Romiplostim N01 combined with immunosuppressive therapy in patients diagnosed with non-severe aplastic anemia, a Phase II study

Yun Zhang, Bo Wang, Dijiong Wu et al. Nov 03, 2025 pp. 6735-6735 10.1182/blood-2025-6735

Abstract Background Aplastic anemia (AA) is a bone marrow failure syndrome characterized by pancytopenia and hypocellula...

Inhibition of NSD2 in t(4;14) myeloma induces changes in mitochondrial priming

Shannon Matulis, Jonathan Patton, Rebecca Owens et al. Nov 03, 2025 pp. 2177-2177 10.1182/blood-2025-2177

Abstract Introduction: Myeloma patients with the t(4;14) subtype are classified as high-risk with lower progression free and overall surviva...

Monoclonal light chain glycosylation is associated with evolution of incidental MGUS

Jemma Larham, Elizabeth Knight, Lauren Campbell et al. Nov 03, 2025 pp. 2185-2185 10.1182/blood-2025-2185

Abstract Introduction: Diagnostic delay remains a challenge in Multiple myeloma (MM), despite evidence that early detect...

Umbilical cord blood microtransplantation as consolidation therapy for elderly patients with newly diagnosed Acute Myeloid Leukemia: A single-center randomized controlled trial

Jingwen Zhang, Yin Liu, Liang Shao et al. Nov 03, 2025 pp. 4189-4189 10.1182/blood-2025-4189

Abstract Background:Acute myeloid leukemia (AML) is a common hematologic malignancy in adults, with a particularly poor prognosis in elderly...

Single-cell transcriptomics reveal long non-coding RNA dysregulation in PPP1R15B-EIF2A axis impairing erythroid maturation in myelodysplastic syndromes

Francisco Beas, Enrique Goñi, Aintzane Diaz-Mazkiaran et al. Nov 03, 2025 pp. 2056-2056 10.1182/blood-2025-2056

Abstract INTRODUCTION: Anemia is the main clinical manifestation of low-risk myelodysplastic syndromes (MDS), reflecting ineffective erythro...

Real-world analysis of ICI-associated HLH reveals early mortality despite standard interventions

Grace Gorecki, Oyepeju Abioye, Srinishant Rajarajan et al. Nov 03, 2025 pp. 4772-4772 10.1182/blood-2025-4772

Abstract Introducion: Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome characterized by excessive i...

Care quality for patients with sickle cell disease and associations with negative descriptors in the electronic medical record

Austin Wesevich, Alexandria Vangelatos, Rajit Hegde et al. Nov 03, 2025 pp. 124-124 10.1182/blood-2025-124

Abstract Introduction We previously demonstrated that patients with sickle cell disease (SCD) have higher odds of negative descriptors in th...

Concurrent loss of TP53 and CDKN2A with tetraploidy predicts richter transformation and poor prognosis in chronic lymphocytic leukemia

Anthony Mansour, Ying Huang, Samon Benrashid et al. Nov 03, 2025 pp. 2133-2133 10.1182/blood-2025-2133

Abstract Background: Richter transformation (RT) can occur in 2-20% chronic lymphocytic leukemia (CLL) patients and has a poor prognosis wit...

Immune checkpoint Inhibitors' impact on outcomes of relapsed and refractory Hodgkin lymphoma: A real-world study

Moath Albliwi, Mohamad-Noor Abu-Hammour, Rahaf Yaghi et al. Nov 03, 2025 pp. 3627-3627 10.1182/blood-2025-3627

Abstract Background Immune checkpoint inhibitors (ICI) have become central to treating relapsed or refractory classical Hodgkin lymphoma (R/R...

Real-world survival, cognitive and health-related quality of life outcomes of methotrexate/ifosfamide plus whole brain radiotherapy for newly diagnosed primary central nervous system lymphoma

Warayoot Luangmaneerote, Natrada Rattanapong, Anthipa Chokesuwattanaskul et al. Nov 03, 2025 pp. 4483-4483 10.1182/blood-2025-4483

Abstract Background: Outcomes for primary central nervous system lymphoma (PCNSL) have been improved with high-dose methotrexate (HD-MTX)/Th...

Accurate and automated multi-center TCD velocity analysis using natural language processing

Sahal Master, Charles Bailey, David Brousseau et al. Nov 03, 2025 pp. 175-175 10.1182/blood-2025-175

Abstract Background: Up to 10% of US children with sickle cell disease (SCD) develop abnormal transcranial Doppler (TCD) velocities, indicat...

Probiotics supplementation ameliorates bone marrow mesenchymal stem cells injury via IFN-I/STAT1 signaling pathway in immune thrombocytopenia during pregnancy

Qi Chen, Jian-Ying Zhou, Meng-Yu Xiao et al. Nov 03, 2025 pp. 1246-1246 10.1182/blood-2025-1246

Abstract Introduction Immune thrombocytopenia (ITP) affects approximately 1 to10 per 10,000 pregnancies. It showed that bone marrow mesenchy...

Efficacy and safety of venetoclax in high-risk Relapsed/Refractory AL amyloidosis: A systematic review and meta-analysis

Muhammad Atif Khan, Abat Khan, Umar Akram et al. Nov 03, 2025 pp. 5747-5747 10.1182/blood-2025-5747

Abstract Introduction AL amyloidosis is a rare plasma cell disorder characterized by the deposition of misfolded light chain proteins in org...

Rapid initiation of cyclosporine and eltrombopag ahead of definitive treatment decreases autoimmunity and expedites marrow recovery in a prospective phase II trial

Nicholas Lee, Ruba Shalhoub, Jennifer Lotter et al. Nov 03, 2025 pp. 979-979 10.1182/blood-2025-979

Abstract Introduction: Severe aplastic anemia (SAA) is characterized by pancytopenia and an empty marrow. Due to multiple diagnostic procedu...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page